Recent Articles

July 17, 2014 10:23 am
Brad Thompson, Ph.D., President and Chief Executive Officer of Oncolytics Biotech
Reoviruses - first isolated in 1951 - are benign viruses with an important property: they are oncolytic, meaning they are capable of infecting and destroying many kinds of cancer cells. The story of how this discovery was made is an exciting one. Read more...
July 15, 2014 11:16 am
Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS
Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...
July 11, 2014 10:52 am
Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus Therapeutics Inc.
The highest-profile symptoms of major diseases are well publicized, yet for many, the side effects of mainstream therapies for these diseases can also impact physical and psychological well-being. Luckily, advances in drug delivery have offered novel treatments. Read more...
July 2, 2014 3:16 pm
Cynthia Fox, Science Editor
Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...
July 1, 2014 1:21 pm
Nancy Dreyfus, Science Writer
To combat the rising costs of bringing a new drug to market, pharmaceutical companies have taken a variety of innovative approaches, according to the U.K. Office of Health Economics, such as deciding earlier in the R&D process to discontinue drugs lacking strong market prospects and better controlling clinical costs. Read more...
June 23, 2014 11:14 am
Nancy Dreyfus, Science Writer
In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...
June 16, 2014 9:54 am
Cynthia Fox, Science Editor
The first small molecule drug discovered with the aid of stem cells - NSI-189, a benzylpiperizine-aminiopyridine - has significantly affected major depressive disorder (MDD) in a small group of patients, Harvard neurologists report this week. Read more...
June 9, 2014 9:37 am
Lori Ball, Chief Operating Officer, BioStorage Technologies
Biospecimens - and the genetic and genomic information derived from these materials - serve as the framework for the translational medicine research used to develop new drugs, novel biomarkers and personalized molecular diagnostics. Read more...     
June 3, 2014 8:44 am
Sean Harper, M.D., Executive Vice President of Research and Development, Amgen
For many decades, scientific advances in cancer treatment were characterized by a slow, non-linear progress that resulted in treatments with a less than stellar ability to target cancer cells. Now, the advent of biomarker-driven drug development and the drive toward personalized medicine have provided a new approach to the treatment of advanced cancer. Read more...
Subscribe to Drug Discovery & Development